The list of recent interview articles

Archive Interviews before 2025

Issue 1060: September 19, 2025

1039Caroline E. Geisler, Ph.D., Assistant Professor, University of Kentucky College of Pharmacy, on paving the way to develop ODN-based therapies to enable weight loss without nausea or vomiting.

Issue 1058: August 29, 2025

1039Eijiro Miyako, Ph.D., Professor at the Materials Chemistry Frontiers Research Area, Japan Advanced Institute of Science and Technology, on developing “AUN,” a new therapeutic approach in which two types of bacteria work in perfect harmony to attack cancer cells.

Issue 1057: August 22, 2025

1057-11057-2 Emily Han, B.S. and Dongyoon Kim Ph.D., Bioengineering Ph.D. Student, NSF Fellow, Pennsylvania University and Bioengineering Postdoctoral Fellow, Pennsylvania University, on leveraging the Mannich reaction to improve LNPs for mRNA delivery.

Issue 1056: August 15, 2025

1039Ying K. Tam, Ph.D., Chief Scientific Officer, Acuitas Therapeutics, on delivering mRNA to a broader range of target cells via a best-in-class LNP delivery platform.

Issue 1054: August 1, 2025

1039Brian Finrow, Co-Founder, Chairman, and CEO, Lumen Bioscience, on leveraging spirulina to achieve the oral delivery of biotherapeutics.

Issue 1053: July 25, 2025

1039Amy Pooler, Ph.D., SVP, Research and Development, Life Edit, on leveraging a unique CRISPR-based approach to develop a novel therapy for the treatment of Huntington’s disease.

Issue 1052: July 18, 2025

1039Dan Theodorescu, M.D., Ph.D., Professor of Urology and Cellular and Molecular Medicine and Nancy C. and Craig M. Berge Endowed Chair for the Director of the Cancer Center, University of Arizona, on exploring the connection between Y chromosome loss and poor outcomes in cancer for men.

Issue 1051: July 11, 2025

1039Jones “Woody” Bryan, Ph.D., President and CEO of Revolo Biotherapeutics, on developing novel therapies for the treatment of autoimmune and allergic disease.

Issue 1050: June 27, 2025

1039Brian P. Head, M.S., Ph.D., Professor at the Department of Anesthesiology, UC San Diego, VA Research Career Scientist, and Scientific Advisory Board Member at Eikonoklastes Therapeutics, on developing a novel gene therapy with neuroprotective effects in both presymptomatic and symptomatic AD.

Issue 1048: June 13, 2025

1039Adam Kepecs, Ph.D., BJC Investigator, Robert J. Terry Professor of Neuroscience, Professor of Psychiatry, Washington University School of Medicine, on discovering the link between a brain-immune system circuit and cancer cachexia-associated apathy.

Issue 1046: May 30, 2025

1039Andree Blaukat, Ph.D., CEO of Tessellate Bio, on leveraging novel synthetic approaches to advance treatments for difficult to treat cancers with high unmet needs.

Issue 1045: May 23, 2025

1039Travis Young, Ph.D., Vice President, Biologics, The Caliber-Skaggs Institute for Innovative Medicines, on Leveraging A Switchable CAR T-Cell Therapy Platform to Reduce Negative Side Effects of CAR T-Cell Treatments.

Issue 1044: May 16, 2025

1039Cameron Pye, Ph.D., Co-Founder and CEO of Unnatural Products, on designing synthetic macrocycles to treat undruggable targets.

Issue 1041: April 25, 2025

1041Roy Maute, Ph.D., Co-Founder and CEO of Pheast Therapeutics, on developing novel macrophage-targeted immunotherapies.

Issue 1039: April 11, 2025

1039William Korinek, Ph.D. and Theodore Liston, Ph.D., CEO and Co-Founder of Astrocyte Pharmaceuticals and Vice-President of Research at Astrocyte Pharmaceuticals, on Pioneering a New Treatment for Injuries to the Brain by Targeting Astrocytes.

Issue 1037: March 28, 2025

1037W. David Arnold, M.D., Executive Director of the NextGen Precision Health initiative, Professor of Physical Medicine and Rehabilitation, Neurology and Medical Pharmacology and Physiology, University of Missouri, on developing a novel potential therapy for age-related weakness.

Issue 1034: February 28, 2025

1034-11034-2 Etienne Sibille, Ph.D. and Thomas Prevot, Ph.D., Scientific Director of the Neurobiology of Depression and Aging Program and the Campbell Chair at the Campbell Family Mental Health Research Institute of the Centre for Addiction and Mental Health and Staff Scientist at the Neurobiology of Depression and Aging Program at the Campbell Family Mental Health Research Institute of the Centre for Addiction and Mental Health, on developing a breakthrough drug with the potential to treat cognitive dysfunction in Alzheimer’s disease.

Issue 1033: February 21, 2025

1036 Nadav Ahituv, Ph.D., Professor, Department of Bioengineering and Therapeutic Sciences, Director, Institute for Human Genetics, University of California San Francisco, on engineering fat cells to suppress tumor cells.

Issue 1031: February 7, 2025

1031Sherri Oberg, CEO and Co-Founder of Particles for Humanity, on developing a solution for the historic issue of instability in vitamin A to treat vitamin A deficiency in areas with high unmet need.

Issue 1030: January 31, 2025

1030 Flaura Winston, M.D., Ph.D., Director of the Innovation Ecosystem Initiative, Children’s Hospital of Philadelphia, on bringing an entrepreneurial perspective to academia.

Issue 1029: January 24, 2025

1029Evonne Sepsis, Founder and Managing Partner of ESC Advisors, on getting biotech clinical assets to a value inflection point.

Issue 1028: January 17, 2025

1028B. Frank Gupton, Ph.D., Chief Executive Officer, Medicines for All Institute at Virginia Commonwealth University, on eliminating waste and inefficiency in the drug manufacturing process.